基于网络药理学探究柴胡疏肝散治疗乳腺增生的作用机制

Exploring the Mechanism of Chaihu Shugan Powder on Mammary Hyperplasia Based on Network Pharmacology

摘要: 目的：通过网络药理学的方法，探究柴胡疏肝散治疗乳腺增生症的潜在靶点和作用机制。方法：使用中药系统药理学数据库与分析平台(TCMSP)筛选柴胡疏肝散的有效活性成分及其作用靶点，利用GeneCards数据库检索乳腺增生症的相关靶点。映射疾病靶点与药物靶点，通过String数据库预测两者间关键靶点的相互作用，构建“药物–有效成分–作用靶点”网络图，并对关键靶点进行基因本体(GO)富集分析和京都基因和基因组百科全书(KEGG)富集分析，分析柴胡疏肝散治疗乳腺增生症的潜在作用机制。结果：共获得50个活性成分，对应作用靶点681个，乳腺增生疾病对应靶点1970个，交集靶点187个，核心靶点37个，并得出排名前10位的GO富集结果和排名前30位的KEGG富集结果。结论：柴胡疏肝散中，槲皮素、山柰酚、柚皮素等多种成分，通过作用于STAT3、AKT1、MAPK3、ESR1、JAK2等靶点，从而调控PI3K/Akt/mTOR、JAK-STAT、TP53-MAPK等通路的信号表达，以发挥治疗乳腺增生的作用。

Abstract: Objective: To explore the potential targets and mechanisms of Chaihu Shugan Powder in the treatment of breast hyperplasia through network pharmacology. Methods: The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was used to screen the effective active components and their targets of Chaihu Shugan Powder. The GeneCards database was utilized to retrieve the related targets of breast hyperplasia. Disease targets and drug targets were mapped, and the interactions between key targets were predicted using the STRING database. A “drug-active component-target” network diagram was constructed, and Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed on the key targets to analyze the potential mechanisms of Chaihu Shugan Powder in treating breast hyperplasia. Results: A total of 50 active components were identified, corresponding to 681 targets. There were 1970 targets associated with breast hyperplasia, with 187 intersection targets and 37 core targets. The top 10 GO enrichment results and top 30 KEGG enrichment results were obtained. Conclusion: Multiple components in Chaihu Shugan Powder, such as quercetin, kaempferol, and naringenin, act on targets like STAT3, AKT1, MAPK3, ESR1, and JAK2, regulating the signal expression of pathways such as PI3K/Akt/mTOR, JAK-STAT, and TP53-MAPK, thereby exerting a therapeutic effect on breast hyperplasia.